Cover Page f or ClinicalTrials.gov 
Document:  
Protocol Version 3.0
Official Study Title:  
A Clinical Utility Study of PrismRA Testing Therapeutic Response for
Rheumatoid Arthritis (DRIVE)  
Document Date: 
October 20, 2022  
   Page 1 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  A Clinical Utility Study of PrismRA Testing Therapeutic Res ponse for 
Rheumatoid Arthritis  (DRIVE ) 
 
Protocol Number: SCIPHER -RA-005 
Version: 3.0 
Date:  20-Oct-2022  
  
 
Sponsor:  
Scipher Medicine  Corporation   
221 Crescent Street, Suite 103A  
Waltham, MA 0245 3 
 
 
 
 
 
 
The information contained in this document is supplied as a background for clinical investigatio
ns.  The document contains proprietary and confidential information that is the intellectual 
property of Scipher Medicine Corporation and shall not be disclosed in whole or in part or used 
for any purpose other than set forth in this protocol without the written consent of Scipher 
Medicine Corporation.  
  
   Page 2 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  Contents  
Protocol Number: SCIPHER -RA-005 .............................................................................................................  1 
1 Key Personnel  ...................................................................................................................................  5 
2 Protocol Signature Page  ...................................................................................................................  6 
3 List of Abbreviation s and Key Terms  ................................................................................................  7 
4 Definitions  ........................................................................................................................................  8 
5 Introduction  ......................................................................................................................................  9 
5.1 Introducti on ..................................................................................................................................  9 
5.2 Rationale  .....................................................................................................................................  10 
6 Study Design  ...................................................................................................................................  10 
6.1 Study Type  ................................................................................................................................ . 10 
6.2 Study population  .........................................................................................................................  11 
7 Study Endpoints  ..............................................................................................................................  12 
7.1 Primary Endpoint  .......................................................................................................................  12 
7.2 Seco ndary Endpoint  ...................................................................................................................  12 
7.3 Exploratory Endpoints  ................................................................................................................  12 
7.4 Patient Selection Criteria  ............................................................................................................  13 
7.4.1  Inclusion Criteria  .................................................................................................................  13 
7.4.2  Exclusion Criteria  ................................................................................................................  15 
8 Study Procedures  ...........................................................................................................................  18 
8.1 Pre-Screening  .............................................................................................................................  18 
8.2 Screening and Enrollment  ..........................................................................................................  18 
8.3 Screen Failures  ...........................................................................................................................  18 
8.4 Summ ary of Visits and Assessments  ..........................................................................................  19 
8.5 Schedule of Visits  .......................................................................................................................  19 
8.6 Schedule of Assessments  ............................................................................................................  21 
8.7 Specimen Collection  ...................................................................................................................  23 
8.8 Study Treatment  .........................................................................................................................  23 
8.8.1  Randomization  ....................................................................................................................  23 
8.8.2  Stratification  .......................................................................................................................  23 
8.8.3  Therapy, Dose, Modes of Administration  ...........................................................................  23 
8.8.4  Duration of Follow -up for Outcome Assessment  ...............................................................  24 
   Page 3 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  8.8.5  Medication Expenses and Reimbursement (PrismRA arm onl y) ........................................  24 
8.9 Data Collection  ...........................................................................................................................  24 
8.10 Patient Follow -up .......................................................................................................................  24 
8.11 Patient Withdrawal/Completion  ................................................................................................ . 25 
9 Safety Assessments  ........................................................................................................................  25 
9.1 Introduction to Safety Assessments  ............................................................................................  25 
9.2 Anticipated and Unanticipated Adverse Device Effects  .............................................................  25 
10 Statistical Considerations  ...............................................................................................................  26 
10.1 Sample size  ................................................................................................................................ . 26 
10.2 Planned Interim Analysis of the PrismRA Arm  .........................................................................  27 
10.3 Baseline Analysis of the External Control Arm  .........................................................................  27 
10.4 Planned Outcome Analysis  .........................................................................................................  28 
10.5 Missing Data Handling  ...............................................................................................................  29 
10.6 Data Reporting  ...........................................................................................................................  29 
10.6.1  Interim Analyses and Reporting  .........................................................................................  29 
10.6.2  Final Analyses and Reporting  ..............................................................................................  29 
11 Limitations  ......................................................................................................................................  30 
11.1 Data Recency  ..............................................................................................................................  30 
11.2 RA Patient Identification  ............................................................................................................  30 
12 Data Handling and Record Keeping (Study Management)  .............................................................  30 
12.1 Study Database  ...........................................................................................................................  31 
12.2 Inspection of Records  .................................................................................................................  31 
12.3 Retention of Records  ..................................................................................................................  32 
12.4 Confidentiality (PrismRA arm Only)  .........................................................................................  32 
12.4.1  Confidentiality of Records  ..................................................................................................  32 
12.4.2  Review of Records  ..............................................................................................................  33 
12.4 .3 Study results  .......................................................................................................................  33 
12.4.4  Future Use of Data or Specimens  .......................................................................................  33 
13 Ethics  ..............................................................................................................................................  34 
13.1 Ethics Review  .............................................................................................................................  34 
13.2 Ethical Conduct of the Study  ......................................................................................................  34 
14 Quality Control  ...............................................................................................................................  34 
14.1 Data Quality  ...............................................................................................................................  34 
   Page 4 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  14.2 Protocol Deviations  ....................................................................................................................  35 
15 Protocol revision history  ................................................................................................................  35 
16 References  ......................................................................................................................................  36 
 
  
   Page 5 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005   
1 Key Personnel  
 
Sponsor:  
 
 
 
 
 
 
  
Sam Asgarian, MD  
Chief Medical Officer  
Scipher Medicine Corporation  
221 Crescent Street, Suite 103A  
Waltham, MA 02453  
 
 
 
  
   
  
   Page 6 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  2 Protocol Signature Page  
Protocol Title: A Clinical Utility Study of PrismRA Testing Therapeutic Response for 
Rheumatoid Arthritis (DRIVE) 
Protocol Version/ Date: 3.0, 20- Oct-2022  
Sponsor Name: Scipher Medicine Corporation 
 
Declaration of Principal Investigator  
I confirm that I have read the above-mentioned protocol and its attachments and understand it. I 
agree to conduct the described study in compliance with all stipulations of the protocol, as well  
as all applicable research regulations and ICH E6 Guideline for Good Clinical Practice (GCP).  
 
Principal Investigator Name: __________________________________________  
 
Principal Investigator Signature:________________________________________ 
 
Date: _____________________________________________________________  
  
   Page 7 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  3 List of Abbreviations and Key Terms  
Abbreviation or Specialist Term  Explanation  
ACR  American College of Rheumatology  
AE Adverse Event  
bDMARD  Biologic Disease Modifying Anti -Rheumatic  Drug  
CAP  College of American Pathologists  
CBC  Complete Blood C ount 
CDAI  Clinical Disease Activity Index  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Comprehensive Metabolic Panel  
CRF Case Report Form  
CRP C-Reactive Protein  
DAS  Disease Activity Score  
csDMARD  Conventional Synthetic Disease -Modifying Antirheumatic Drug  
DMARD  Disease Modifying Anti -Rheumatic  Drug  
DNA  Deoxyribonucleic Acid  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
EMR  Electronic Medical Records  
ESR Erythrocyte Sedimentation Rate  
FDA  Food and Drug Administration  
GCP  Good Clinical  Practice  
GPP Good Pharmacoepidemiology Practices  
HIPAA  Health Insurance Portability and Accountability Act of  1996  
ICF Informed Consent Form  
ICH International Council for Harmonization  
IL-1i Interleukin -1 inhibitor  
IL-6i Interleukin -6 inhibitor  
IL-17i Interleukin -17 inhibitor  
IL-23i Interleukin -23 inhibitor  
IQR Interquartile Range  
IRB Institutional Review Board  
JAKi Janus Kinase  inhibitor  
MCID  Minimal Clinically Important Difference  
MID  Minimal Important Difference  
MOA  Mechanism of Action  
MTX  Methotrexate  
NSAIDs  Non-Steroidal Anti -Inflammatory Drug  
PRO  Patient Reported Outcomes  
PtGA  Patient Global Assessment  
   Page 8 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  Abbreviation or Specialist Term  Explanation  
RA Rheumatoid Arthritis  
RAPID3  Routine Assessment of Patient Index Data  3 
RDCI  Rheumatic Disease Comorbidity Index  
RNA  Ribonucleic Acid  
SAE Serious Adverse Event 
SD Standard Deviation  
SOC  Standard of Care 
TB Tuberculosis  
TNFi Tumor Necrosis Factor  Inhibitor  
tsDMARD  Targeted small molecule Synthetic Disease Modifying Anti -Rheumatic Drug  
UADE  Unanticipated Adverse Device Effect  
US United States  
 
4 Definitions  
Terms  Definition  of Terms  
DRIVE Study  The comparative effectiveness study of the PrismRA tes t comparing the clinical 
outcomes of patients in the PrismRA  arm (trial)  and the external control arm  
(observational) . 
Baseline  Assessments  of patient s as they enter  the PrismRA arm . For the external control 
arm, the corresponding baseline CDAI assessment window  is the 3 -month 
period before the index date  (defined as the time of study treatment  initiation) . 
For medical history all available data before the index date will be used in t he 
external control arm.  
Enroll ment  The point at which the patient signs the informed consent form  for the PrismRA 
arm. Not applicable for the external control arm .   
PrismRA arm  Trial participants  in the trial conducted by Scipher Medicine  for whom  
PrismRA test is performed and the Investigator will use the PrismRA test results 
to inform the treatment decision.  
External control 
arm OM1 real -world data p atient s who receive d standard of care treatment for RA  
with TNFi or non -TNFi b/tsDMARDs without guidance from PrismRA test 
results.  
Study Treatment  The b/tsDMARDs (FDA approved for RA) that is initiated at Vis it 2 (See 
Section 8.5) , informed by the PrismRA  test in the PrismRA arm and as a part of 
standard of care in the external control arm. This study treatment 
(b/tsDMARDs) can be the very first b/tsDMARD for the patient or a subsequent 
b/tsDMARD after having used one or more TNFi b DMARDs (but not non -
TNFi b/tsDMARDs).  
Study Treatment 
Initiation  The point at which a study treatment (See “Study Treatment” above)  is initiated  
to treat RA. This time point constitutes the index date  (beginning of the follow -
up) and is defined as Visit 2  
   Page 9 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  Terms  Definition  of Terms  
RA Disease 
Activity  Disease activity is based on the CDAI  score as follows:  
• Remission: CDAI ≤ 2.8  
• Low: CDAI > 2.8 and ≤ 10.0  
• Moderate: CDAI > 10.0 and ≤ 22.0  
• High: CDAI > 22.0  
For the PrismRA  arm, the CDAI scores will be assessed by the Investigator. 
The CDAI scores for the external control arm in OM1 Prem iOM RA consist of 
CDAI scores in structured EMR data, and CDAI scores estimat ed by machine 
learning based on unstructured data .1CDAI scores from all data sources will be 
used.  
5 Introduction  
5.1 Introduction  
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic 
inflammation primarily involving the joints of the hands and wrists. RA typically presents with 
generalized morning stiffness and musculoskeletal pain followed by joint swelling and 
tenderness. Untreated RA often leads to progressive joint deformity and destruction with 
subsequent disability. The objectives of RA treatment are to stop disease progression, prevent 
irreversible joint destruction, and improve quality of life. Ideally, rheumatologists consult with 
their patients to decide whether disease remission (the absence of signs or symptoms of 
significant inflammatory disease) or low disease activity is the appropriate goal of treatme nt. 
After therapy is started, RA disease activity is measured regularly utilizing one of several 
validated tools (e.g., DAS, CDAI). Using the treat- to-target approach, therapeutic adjustments 
are made each visit to ensure continued progression to the agreed treatment target. 
To achieve these treatment goals, there are an increasing number of advanced biologic and small 
molecule targeted therapies (e.g., b/tsDMARD) directed at specific components of the immune 
system involved in RA pathogenesis. Treatment options organized by mechanism of action 
(MOA ) include tumor necrosis factor-α inhibitors ( TNFi ), Janus kinase inhibitors ( JAKi ), 
interleukin-6 inhibitors (IL-6i), interleukin-1 inhibitors (IL-1i), T cell co-stimulation inhibitors, 
and B cell modulators. For approval by the Food and Drug Administration (FDA), these agents 
are required report clinical trial data using ACR20, 50, and 70, defined as a 20%, 50%, and 70% 
improvement respectively in specific disease measures: swollen joint count, tender joint c ount, 
patient reported outcomes, physician reported outcomes and acute phase reactant measures2.  
Unfortunately, all of these agents report ACR50 response rates of only 25-40% at six months 
following treatment initiation3-6. Hence, two thirds of RA patients receiving their first 
b/tsDMARD fail to achieve ACR50, regardless of the MOA.  
 
The goal of precision medicine is to match patients with a treatment MOA that most clos ely 
matches his or her individual disease biology to improve disease outcomes in a timely fashion. 
Precision medicine has been most successful in oncology where genetic (DNA) changes in 
patient tumors are analyzed in order to identify the best treatment options for each individual. 
However, DNA data alone is insufficient to determine individual treatment options in complex 
diseases such as RA. Scipher Medicine is using network medicine and artificial intellige nce to 
   Page 10 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  bring precision medicine to complex diseases through a combined analysis of gene expression 
(RNA) data, clinical metrics, and appropriate laboratory markers. PrismRA® is the first test 
developed using Scipher’s network medicine approach. 
 
PrismRA was developed because the majority of RA patients receive a TNFi therapy as their 
b/tsDMARD7,8. It is a molecular signature test designed to predict the likelihood that a RA patient 
will be a non-responder to TNFi therapies. From a single blood draw taken before the start of 
treatment, the PrismRA test assesses twenty-three (23) biomarkers that are integrated i nto a 
single predictive model that generates a score on a scale of one (1) to twenty-five (25) that 
represents the likelihood of non-response to TNFi therapies. In a prior PrismRA validation study, 
patients with a molecular signature of non-response were less likely to have an adequate 
response to TNFi therapies than those patients lacking the signature according to ACR50, 
ACR70, CDAI, and DAS28-CRP with significant odd ratios of 3.4-8.8 for targeted therapy naïve 
patients and 3.3-26.6 for TNFi-exposed patients10.  
5.2 Rationale  
The objective of the DRIVE study is to establish the clinical utility of the PrismRA t est in 
evaluating therapeutic response for patients with rheumatoid arthritis (RA).  
6 Study Design  
6.1 Study Type  
This is a two-arm, multi-center United States (U.S.)-based study with a prospective, non-blinded 
intervention arm (PrismRA arm) and an observational external control arm designed to 
demonstrate the clinical utility of the PrismRA test in routine clinical care. The study w ill 
compare outcomes for RA patients with moderate to high disease activity whose treatment  is 
informed by PrismRA test results (PrismRA arm) to outcomes among RA patients who receive 
the standard of care (SOC) not informed by PrismRA results (external control arm).  
 
PrismRA arm: 
In this arm, all patients will receive the PrismRA test. The Investigator will receive the PrismRA 
results and use those results to inform treatment selection by Visit 2. Patients may be foll owed 
indefinitely from the time of signing the informed consent and medical records release form 
unless the patient withdraws from the study, dies, or becomes lost to follow-up. Changes to the 
study b/tsDMARDs do not terminate follow-up. A patient can withdraw from the study at any 
time.  
 
External control arm: 
The observational external control arm will consist of comparable initiators of b/tsDMARDs i n 
OM1’s PremiOM RA dataset, in which the specific choice of TNFi or non-TNFi b/tsDMARDs 
was based on the treating physician’s clinical judgement and was not informed by the PrismRA 
test results. Baseline as well as follow-up data will consist of data obtained at routine  clinical 
encounters. The index date (start of follow-up) for this external control arm will be defined as the 
time of initiation of the study treatment (very first or subsequent b/tsDMARDs) and patients wil l 
be followed until week 24, death, or loss to follow-up, whichever occurs first. Changes to the 
   Page 11 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  study b/tsDMARDs do not terminate follow-up. Controls may be sampled from time intervals 
contemporaneous with the trial (March 2022 and onward) as well as historical periods. 
 
6.2 Study population  
PrismRA arm: 
This arm will enroll approximately 600 RA patients at approximately 33 clinical sites w ho are at 
least 18 years of age. All patients in the PrismRA arm will undergo PrismRA testing at thei r first 
study visit (Visit 1). See Patient Selection Criteria for details. 
 
External control arm: 
Patients with RA in the OM1 PremiOM RA Dataset  will be selected based on the same eligibility 
criteria as in the PrismRA arm and adapted for real-world data availability where necess ary. 
Patients in the external control arm will be balanced with patients in the PrismRA arm  using a 
propensity score model developed with the primary goal of achieving balance in baseline 
characteristics between the comparison groups. The external control arm is expected to have at 
least 1,500 eligible patients after propensity score modeling, with no less than 750 patients 
having CDAI scores at both baseline and Week 24. The data from patients who initiated 
b/tsDMARDs in the contemporaneous period (March 2022 and onward) and if needed, the recent 
historical period (6-month to 3-year period prior to March 2022) will be used to maximize the 
size of the patient pool while minimizing confounding by the potential secular trends in 
treatment patterns. The smallest historical time window that can provide the planned num ber of 
external control arm patients comparable to the PrismRA arm patients will be use d. The overlap 
in propensity score distributions between the external control and trial arms will inform the 
ultimate sample size.   
 
The data source for the analysis is the OM1 PremiOM RA Dataset within the OM1’s Real-World 
Data Cloud (OM1, Inc, Boston, MA, US). The OM1 Real-World Data Cloud is derived from 
deterministically linked, de-identified, individual-level health care claims, electroni c medical 
record (EMR), and other data. EMR data are from sources geographically representative of the 
U.S. population and include medication history and prescription information, laboratory results, 
and diagnoses as documented by a physician. Additional medical and pharmacy claims data are 
linked to the clinical data to fill gaps in patients’ clinical care. The medical and pharma cy claims 
contain billing and coding history on inpatient and outpatient encounters from acute care 
facilities, ambulatory surgery centers, and clinics. The OM1 Real-World Data Cloud includes 
data from January 2013 to present day.   
 
To qualify for the OM1’s PremiOM RA dataset, each patient must be at l east 16 years old at the 
time of the qualifying diagnosis and meet at least one  of the following conditions: 
● At least two diagnosis codes for RA, at least 30 days apart, each coming from an 
encounter with a rheumatologist 
● At least one inpatient RA diagnosis code 
● At least two outpatient RA diagnosis codes, at least 30 days apart and within a year, 
regardless of physician specialty 
   Page 12 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  ● At least one outpatient RA diagnosis code and a prescription or fill for a DMARD and no 
diagnosis for any of the non-RA conditions for which those drugs may also be prescribed 
Non-RA conditions are defined as juvenile idiopathic arthritis, psoriatic arthritis/psoriasis, 
ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, cryopyrin-
associated periodic syndromes, renal transplant, malaria, systemic lupus erythematosus, gia nt 
cell arteritis, cytokine release syndrome, all cancers, hydatidiform mole. 
7 Study Endpoints   
7.1 Primary Endpoint  
The proportion of patients with moderate or high disease activity at baseline who achieve  a 
minimal important difference (MID)  11 in CDAI of ≥ 6 (baseline moderate) or ≥12 (baseline high) 
at 24 weeks after study treatment initiation.  
 
7.2 Secondary Endpoint  
Secondary endpoints include the following: 
 
a) The proportion of patients with moderate or high disease activity at baseline who achieve 
CDAI  ≤ 10 (low disease activity (LDA))  or CDAI ≤ 2.8 (remission) at 12 and 24 weeks 
after study treatment initiation 
b) The change in CDAI scores from baseline to 12 and 24 weeks among patients with 
moderate or high disease activity at baseline who initiate study treatment. 
c) The proportion of patients with moderate or high disease activity at baseline who achieve 
an MID in CDAI of ≥ 6 and ≥12, respectively, 12 weeks after study treatment initiation  
d) The proportion of patients with moderate or high disease activity at baseline who achieve 
a meaningful reduction (defined as ≥ 10 on the scale of 0–100) of patient global 
assessment  (PtGA) compared to the baseline PtGA 12 and 24 weeks after study 
treatment initiation.  
e) The proportion of patients with moderate or high disease activity at baseline who achieve 
a minimal clinically important difference ( MCID ) in RAPID3 (≥ 3.8 on the scale of 0–
30)12compared to the baseline RAPID3 at 12 and 24 weeks after study treatment 
initiation. 
f) The proportion of patients with moderate or high disease activity at baseline who achieve 
an MCID in  patient pain visual analogue scale  13(≥ 1.1 on the scale of 0–10) compared 
to the baseline pain at 12 and 24 weeks after initiation of a b/tsDMARD therapy.  
g) The proportion of treatment decisions  that were guided by PrismRA test results (in the 
PrismRA arm only) 
 
7.3 Exploratory Endpoints  
• The proportion of moderate to high disease activity patients that achieve ACR50  
therapeutic response 12 and 24 weeks after study treatment initiation (in the PrismRA 
arm only; analysis in the external control arm may only be descriptive in nature if the 
constructed ACR50 is not sufficiently available in real world data). 
   Page 13 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  • The proportion of patients receiving TNFi therapy  and non-TNFi b/tsDMARDs as the 
study treatment at the index date. 
• The number of patients that stop or change the study treatment due to an intolerance 
during the 24-week follow-up period (in the PrismRA arm only; analysis in the external 
control arm may only be descriptive in nature if the reason for the study treatment 
discontinuation is not sufficiently available in real world data). 
 
7.4 Patient Selection Criteria  
7.4.1 Inclusion Criteria 
Table 1  shows the inclusion criteria that will be used prospectively in the PrismRA arm and the 
best approximation for the selection of comparable patients in the observational external control 
arm. 
 
Table 1. Inclusion  criteria  by study arm 
 PrismRA arm  External control arm  
1 Patient is eighteen years of age or older (≥  18) at 
time of consent . All patients  are ≥ 18 years at the initiation of 
b/tsDMARDs  (which can be the first ever 
b/tsDMARD or subsequent b/tsDMARD s). 
2 Patient must meet the criteria for RA as defined 
by the 2010 ACR/EULAR classification at Visit 
1. Patients  are in the OM1 Premi OM RA  dataset 
(See Section 6.2 Study Population) . 
3 Patient has active, moderate to severe  RA with a 
CDAI of  >10 at Visit 1 . Patient has a CDAI of  > 10 based on  the most 
recent  CDAI  assessed  during the 3-month period 
prior to the b/tsDMARDs initiation.  
4 Patient has swollen and tender joint count of  ≥ 2 
each, as determined by CDAI assessment at Visit 
1 using a 28 -joint count . Patient has s wollen and tender joint counts of  ≥ 2 
each, based on the  most recent  joint counts 
assessed during the 3-month period prior to the 
b/tsDMARDs initiation.  
   Page 14 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  5 Patient is eligible for treatment with any 
b/tsDMARD therapy at Visit 1 based on all of the 
following:  
 
• Investigator determination that patient 
satisfies clinical criteria  
• Patient consents to the use of non -csDMARD 
therapy during shared investigator -patient 
decision making  
• Absence of any financial or logistical 
limitations to the initiation of a b/tsDMARD 
therapy  Only p atients who initiate a  b/tsDMARD  will be 
enrolled  to ens ure the treating rheumatologist 
determination of indication, patient consent, and 
financial/logistical feasibility . 
 
The list of b/tsDMARDs approved for RA 
includes the following:  
• TNFi (infliximab, etanercept, certolizumab 
pegol, golimumab, adalimumab)  
• IL-6i (tocilizumab, sarilumab)  
• IL-1i (anakinra)  
• T-cell co -stimulation inhibitor (abatacept)  
• B-cell depletion agent (rituximab)  
• JAKi (tofacitinib, baricitinib, upadacitinib)  
 
Biosimilars/generics of these b/tsDMARDs  will 
also be included.  
6 Concomitant treatments including but not limited 
to the following are permitted per standard of 
care:  
• csDMARDs (e.g., methotrexate, 
sulfasalazine, leflunomide, or 
hydroxychloroquine)  
• Non-steroidal anti -inflammatory drugs 
(NSAIDs)  
• Corticosteroids  
• Prednisone  (or equivalent) at a stable ≤ 10 
mg per day for at least 2 weeks prior to Visit 
1 
• Intra -articular or parenteral corticosteroids ≤ 
2 weeks prior to Visit 1  Concomitant treatments  per standard of care  will 
be allowed and recorded .  
7 Patient is willing and able to complete the 
informed consent process and comply with study 
procedures and visit schedule . This criterion is not replicable with real world 
dispensing data and will not be used.  
  
8 This additional point does not apply to the 
PrismRA arm.  Patients will have ≥ 1 CDAI  measured  in the 3 -
month period prior to the b/tsDMARD initiation 
to ensure patients from practices where CDAIs 
are routinely used  and baseline CDAI is well 
defined  in this  3-month window . There will be a 
further require d ≥ 3 CDAI measurements in the 
12-month period prior to the b/tsDMARD 
initiation. If possible to  retain enough patients to 
fully match the PrismRA arm, there will be a 
   Page 15 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  require d ≥ 4 CDAI measurements in the 12 -
month period prior to the b/tsDMARD initiation.  
 
To ensure sufficient medical history information 
and past b/tsDMARDs usage history, at least  12 
months  of enrollment in the database prior to the 
study treatment  initiation  will be required . All 
history  information prior to 12 months will also 
be utilized.  
 
7.4.2 Exclusion Criteria  
 
Table 2  shows the exclusion criteria that will be used prospectively in the PrismRA arm and the 
best approximation for the selection of comparable patients in the observational external control 
arm. 
 
 
Table 2. Exclusion criteria by study arm   
PrismRA arm  External control arm  
1 Patient has any non -study limitation precluding patient 
receipt of the PrismRA test (e.g., financial, or 
logistical limitations).  
  The assumption will be made that patients 
who used b/tsDMARDs did not have such 
limitations that would have prevented the 
potential receipt of the PrismRA test had it 
been offered.  
2 Concurrent treatment with an investigational product 
or use of an investigational product less than 4 weeks 
prior to Visit 1.  
  This criterion is not replicable with real 
world dispensing data and will not be used.  
3 Patient cannot have participated in an observational 
study at least 4 weeks prior to Visit 1.  
  This criterion is not replicable in real -
world data and will not be used.  
4 The use of RA therapies outside of FDA -approved 
indication.  
  This criterion is not replicable with real -
world dispensing data and will not be used.  
   Page 16 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  5 Patient has been previously exposed to any non-TNFi 
b/tsDMARD s (FDA approved or experimental).   Patients who have been previously exposed 
to any non-TNFi b/tsDMARDs any time 
during their history  prior to the study 
treatment initiation  will be excluded . 
 
The list of non -TNFi b/tsDMARDs 
approved for RA includes the following:  
• IL-6i (tocilizumab, sarilumab)  
• IL-1i (anakinra)  
• T-cell co -stimulation inhibitor 
(abatacept)  
• B-cell depletion agent (rituximab)  
• JAKi (tofacitinib, baricitinib, 
upadacitinib)  
 
The list of non -TNFi b/tsDMARDs not 
currently approved for RA includes the 
following:  
• IL-23i (guselkumab, risankizumab , 
tildrakizumab , ustekinumab [IL -12/IL -
23i]) 
• IL-17i (secukinumab, ixekizumab, 
brodalumab)  
6 Women who are known to be pregnant or breast -
feeding or plan to get pregnant during the study.  Patients who have relevant pregnancy -
related codes in the past 12 months or 
during the 24 -week follow -up will be 
excluded .  
7 Patient is currently receiving systemic antimicrobial 
treatment for viral, bacterial, fungal, or parasitic 
infection at the time of Visit 1.   Patients who received antimicrobial 
medications in the 30 -day period prior to 
the b/tsDMARD initiation  will be 
excluded .  
   Page 17 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  8 Patient has any active, chronic, or recurrent invasive 
infection (e.g., listeriosis and histoplasmosis) and/or a 
viral infection, that based on the Investigator’s clinical 
assessment, makes the patient an unsuitable candidate 
for the study.  This includes hepatitis B virus (HBV) or 
hepatitis C virus (HCV), recurrent or disseminated 
(even a single episode) herpes zoster, disseminated 
(even a single episode) herpes simplex, or human 
immunodeficiency virus (HIV).  
  Patients with the relevant diagnostic codes 
for chronic, or recurrent invasive infections  
any time  prior to the study treatment  
initiation.  
 
This includes listeriosis, histoplasmosis,  
coccidioidomycosis,  tuberculosis,  non-
tuberculosis mycobacterial infections , 
cryptococcosis, pneumocystis pneumonia,  
toxoplasmosis,  HBV, HCV, varicella 
zoster virus (VZV), herpes simplex virus 
(HSV), HIV.   
9 Patients with malignancy except non -melanoma skin 
cancer, localized prostate cancer treated with curative 
intent with no evidence of progression, low risk or 
very low risk (per standard guidelines) localized 
prostate cancer under surveillance/watchful waiting 
(without intent to treat), or carcinoma in situ of any 
type (complete resected).   Patients with cancer diagnostic codes any 
time prior to the study treatment  initiation  
will be excluded . This includes all 
malignancies except non -melanoma skin 
cancer.  
 
Allowing for localized and cured cancers is 
not replicable in real -world data and will 
not be attempted.   
10 Patients who are unable to understand the protocol and 
unable to provide informed consent.  
  This criterion is not replicable in real-
world data and will not be used.  
11 Patients who are not indicated for PrismRA.   
  This criterion is not replicable in real-
world data and will not be used.  
 
The assumption will be made that the  
careful replication of the above inclusion 
and exclusion criteria will ensure a 
comparable indication for PrismRA in the 
external control arm.   
12 This point does not apply to the PrismRA arm.  Patients will be excluded if they have been 
cared for by rheumatologists who have 
participated  in the PrismRA arm  any time 
in the past  to avoid including patients using 
PrismRA.  
 
   Page 18 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  8 Study Procedures  
8.1 Pre-Screening  
PrismRA arm: 
Prior to Visit 1, potential patient charts may be reviewed to determine eligibility for the study.  
At the discretion of the Investigator, pre-screening lab tests (i.e., Complete Blood Count (CBC), 
Clinical Metabolic Panel (CMP), Tuberculosis ( TB), and/or C-reactive Protein (CRP)) may be 
ordered and analyzed per standard of care if the patient has not already received these lab tests 
within 3 months of the planned study Visit 1. 
External control arm: 
The entirety of data for each patient (no less than 12 months) prior to the study treatment 
initiation will be used to assess their medical history and past medication use and to de termine 
their eligibility (see above). For variables required to be up to date at the time of the study 
treatment initiation, the most recent value within the 3-month period prior to the study treatm ent 
initiation will be used, unless otherwise stated (see Table 1, Table 2). 
 
8.2 Screening and Enrollment  
PrismRA arm: 
At Visit 1, patients will complete the informed consent process. A writ ten, signed informed consent 
form (ICF) must be obtained prior to the recording or collection of any data under this protocol . 
Upon signing the ICF, the patient will be considered enrolled into the study.  
At the discretion of the Investigator, patients will also be asked to revie w and sign a medical 
records release form providing access to their medical records outside of the st udy. Sponsor or 
Sponsor designees may access patients’ medical records upon study completion for only those 
patients that provide proper authorization.  
Following patient consent, each patient will be assigned a unique study ident ification number that 
will be used to track their de-identified data throughout their participation in the study. 
 
External control arm: 
Screening/enrollment activities are not applicable for the external control arm of patients 
identified from real-world data.    
 
8.3 Screen Failures  
PrismRA arm: 
Screen failures are defined as those patients who consent to participate in the clinical  study but 
did not meet one or more criteria for participation in the study. 
 
External control arm: 
Non-initiators of b/tsDMARDs are considered screen failures and will not be in the analysis 
dataset. 
   Page 19 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005   
8.4 Summary of V isits and Assessments   
PrismRA arm: 
Data  will be collected at Screening/Baseline, Study Treatment Initiation (2–6 weeks afte r, and 
then at follow up visits approximately 12 week s and 24 week s after Study Treatment Initiation. 
The allowable time windows are explained in Section 8.5. 
 
External control arm: 
Data from clinical encounters over time will be used to provide information for (1) the baseline 
period (for CDAI assessment), (2) study treatment initiation time point; (3) the 12-week follow-
up period; and (4) the 24-week follow-up period. The allowable time windows are explained in 
Section 8.5. 
 
8.5 Schedule of Visits  
 
 
PrismRA arm: 
The timing for the follow-up visits (visits 3 and 4) should be projected based on the date of Study 
Treatment Initiation (index date).  
 
External control arm: 
The date of study treatment initiation constitutes the index date for the beginning of the follow-
up. The 3-month period prior to the index date will be used to ascertain the baseline CDAI. The 
12-week follow-up will be defined as the clinical encounter closest to the 12-week time point 
within the 12 ( ± 4) week  visit window. The 24-week follow-up will be defined the visit closest to 
the 24-week time point within the 24 ( ± 4) week visit window. Depending on feasibility, we will Baseline CDAI 
most recent 
within 3 months 
of index date12 (±4) 
week 
CDAI 24 (±4) 
week 
CDAI External 
Control 
ArmPrismRA
Arm
12 (±2) 
week 
CDAI 24 (±2) 
week 
CDAI Baseline CDAI 
2-6 weeks prior 
to index dateIndex date
Study 
b/tsDMARD
initiation
Visit 1 Visit 2 Visit 3 Visit 4
Visit 1 Visit 2 Visit 3 Visit 4
   Page 20 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  attempt follow-up windows, such as ± 6 week window, ± 3 week window, and ± 2 week 
window. Sensitivity analyses with different follow-up windows will be conducted as needed. 
  
   Page 21 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  8.6 Schedule of Assessments  
PrismRA arm: 
 
Procedure  Visit 1 
(Screening/ 
Baseline)  Visit 2  
(Study 
Treatment 
Initiation)7 Visit 3  
(12 Week  
Follow -up) Visit 4  
(24 Week 
Follow -up) 
Visit Windows  N/A 2-6 weeks  ±2 weeks  ±2 weeks  
Informed Consent  X    
Medical Records Release Form  X    
Eligibility Criteria  X    
RA Medical History  X    
Smoking8    X 
Comorbidities8    X 
Weight  X  X X 
28 Joint -Count for Tenderness & Swelling X  X X 
PrismRA1 X    
CRP2 X  X X 
RF3     
Vectra DA3     
TB Test4     
Urine Pregnancy Test5     
Physician Global Assessment of Disease Activity X  X X 
Patient Global Assessment of Pain  X  X X 
Patient Global Assessment of Disease Activity  X  X X 
Health Assessment Questionnaire  X  X X 
RAPID3 Assessment  X  X X 
Imaging6     
Targeted Therapy Questionnaire X X   
RX Adherence Check   X X 
Initiation or Change of Targeted Therapy  X   
Current RA Medications  X X X X 
Socioeconomic  Status8    X 
Abbreviations: CRP (C -Reactive Protein), N/A (Not Applicable), RA (Rheumatoid Arthritis), RF (rheumatoid factor), and RX 
(Treatment) . 
Note: At the discretion of the Investigator, pre -screening standard of care lab tests ( e.g., CBC, CMP, and /or CRP) may be ordered 
if patient does not have lab tests within 3 months of Visit 1.  
1 PrismRA results  will be provided to the Investigator  based on the patient’s assigned treatment selection arm.  Investiga tors will 
receive the test results only for those patients in the  informed treatment selection arm.  
2 Performed via standard lab practices utilizing the s ame local lab.  Visit 1 results can be from a test within 3 months prior to Visit 
1. 
3 If available, results can be provided from patient’s  medical records.  
4 If required by the Investigator , test can either be QuantiFERON Gold TB Test, local PPD TB test, o r T-Spot. 
5 If required by the Investigator, a urine pregnancy test for c hild-bearing pot ential females should be completed . 
   Page 22 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  6 If available, r esults for imaging (e.g., X -rays, ultrasound, magnetic resonance imaging, or total sharp score) to be pulled from 
patient ’s medical records . 
7 PrismRA results must be received and reviewed prior to study  treatment initiation  for the PrismRA  arm only . 
8 Smoking, comorbidities , and socioeconomic status information  collected at Visit 4 reflect s patient’s status at Baseline.  
 
External control arm: 
No prospective data collection schedule is enforced, and the data collection is based on routi ne 
clinical encounters. Existing data will be mapped from these routine clinical encounters  in the 
following manner. 
 
Data Element  Baseline  Study 
Treatment 
Initiation 12 Week  
Follow -up Visit 4  
(24 Week 
Follow -up) 
Visit Windows  
3 months  (Precise  index  
date) ±4 weeks  ±4 weeks  
Informed Consent  X    
Medical Records Release Form  X    
Eligibility Criteria  X    
RA Medical History  X    
Smoking  X    
Comorbidities  X    
Weight  X  X X 
28 Joint -Count for Tenderness & Swelling X  X X 
PrismRA1 N/A    
CRP X  X X 
RF X    
Vectra DA N/A    
TB Test  N/A    
Urine Pregnancy Test N/A    
Physician Global Assessment of Disease Activity X  X X 
Patient Global Assessment of Pain  X  X X 
Patient Global Assessment of Disease Activity  X  X X 
Health Assessment Questionnaire  X  X X 
RAPID3 Assessment  X  X X 
Imaging6 N/A    
Targeted Therapy Questionnaire N/A    
RX Adherence Check  (defined as continuation of the 
study treatment )   X X 
Initiation or Change of Targeted Therapy  N/A   
Current RA Medications  X  X X 
Socioeconomic  Status1 X    
Abbreviations: CRP (C -Reactive Protein), N/A (Not Applicable), RA (Rheumatoi d Arthritis), RF (rheumatoid factor), and RX 
(Treatment).  
1 Socioeconomic  status information will be available for a subset of pa tients . 
 
   Page 23 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005   
8.7 Specimen Collection  
PrismRA arm: 
Blood will be collected at Visits 1, 3, and 4. Blood will not be collected at Visit 2. 
Blood will be collected in two 2.5 mL PAXgene tubes and one 8-10 mL serum separator tube for 
a total of 15 mL at Visit 1. Blood will be collected using the PrismRA sample collection kit  at 
Visit 1 and processed according to the study sample collection process. Blood for the CRP test 
will be collected at Visits 1, 3, and 4 utilizing the same local lab and processed per standa rd lab 
practices.   
Anticipated volume of blood to be drawn per patient over the scheduled study visits should not 
exceed 45 mL. If the initial blood draw in Visit 1 fails sample quality assessments, a patient may 
have an unscheduled study visit performed for an additional blood draw prior to Visit 2. 
External control arm: 
No specimen collection schedule is enforced, and the specimen collection is based on routine 
clinical encounters. OM1 does not handle specimens and utilizes the laboratory results only. 
 
8.8 Study Treatment  
PrismRA arm: 
Patients are to initiate a b/tsDMARD or change to a study-indicated b/tsDMARD per clinical 
guidance of the Investigator on Visit 2. 
 
External control arm: 
b/tsDMARDs initiated by the treating physician according to the standard of care will be deem ed 
as the study treatment. The study treatment can include the very first b/tsDMARD (new 
initiation) or subsequent b/tsDMARD (switch). 
 
8.8.1 Randomization 
No randomization will be performed for this study. 
 
8.8.2 Stratification 
There will be no stratification for this study. 
 
8.8.3 Therapy, Dose, Modes of Administration 
PrismRA arm: 
• Dosage and selection of b/tsDMARD are at the Investigator’s discretion but should be 
within the FDA approved label. 
• Dose adjustments for a particular b/tsDMARD will be permitted only in accordance with 
the FDA approved label. Changes should be documented in the patient’s medical records. 
 
External control arm: 
   Page 24 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  The selection and the initial dosage and dose adjustments are at the discretion of the treat ing 
physician and are assumed to be compatible with FDA approval. 
 
8.8.4 Duration of Follow-up for Outcome Assessment 
• 24 weeks from the index date, defined as the date of b/tsDMARDs initiation (See Section 
8.5 for allowable time windows)  
 
8.8.5 Medication Expenses and Reimbursement (PrismRA arm only) 
• The Sponsor will not cover any b/tsDMARD medication costs associated with this study. 
• Patients may be reimbursed for their time at the discretion of the Investigator.  
 
8.9 Data Collection  
PrismRA arm: 
Patient data will be collected from clinical assessments, medical records, im aging, laboratory 
results, and surveys at screening/baseline, treatment initiation and follow-up visits and ente red in 
the study database. 
 
If a completed medical records release form is on file, comprehensive demographic, medical, and 
health information (if available) may be directly collected from the patient’s electronic me dical 
records by the Sponsor. Electronic Medical Records (EMR) data may be obtained indefinitely 
following a patient’s enrollment unless the patient withdraws authorization.  
 
Data  from the PrismRA (Visit 1) samples will be stored at Scipher Medicine’s Clinical 
Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists 
(CAP)-accredited laboratory. 
 
External control arm: 
In the external control arm, the existing data in OM1’s PremiOM RA will be utilized. No new 
data collection will be performed. 
 
8.10 Patient Follow -up 
PrismRA arm: 
In order to reduce the loss of patients to follow-up, all patients will be asked for their personal 
contact information and an alternate person’s contact information. Patients may be direct ly 
contacted by the Investigator or Sponsor/designee in order to support study follow-up. The 
designated alternate contact person may also be directly contacted in the event the patie nt cannot 
be reached. 
 
For patients who are lost to follow-up, Investigator or Sponsor/designee will search available 
health status databases to determine vital status and cause of death in case of mortal ity. 
 
External control arm: 
   Page 25 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  To ensure the availability of sufficient quality of data, at least one CDAI measurement during t he 
baseline 3-month period prior to the index date (initiation of b/tsDMARDs) will be required. As 
needed, we will further require CDAI during the follow-up. 
 
8.11 Patient Withdrawal/Completion  
PrismRA arm: 
Patients may withdraw from the study at any time without prejudice to their care.   
The Investigator and/or the Sponsor may withdraw patients at any time who violate the study 
protocol or, to protect the subject for safety or administrative reasons at any time. It will be 
documented whether or not each patient completes the determined follow-up visits. Changes to 
the study treatment during follow-up as indicated by clinical practice does not constitute a 
protocol violation or withdrawal. 
 
Early withdrawals will include, but are not limited to, those patients who consent to partici pate in 
the clinical study but fail to initiate a b/tsDMARD at Visit 2 within 6 weeks of Visi t 1. 
 
 
External control arm: 
As existing data from routine clinical care will be utilized, this point does not apply. 
 
9 Safety Assessments  
9.1 Introduction to Safety Assessments  
PrismRA arm: 
There are no investigational therapies being evaluated per the protocol. For patients in the 
informed treatment selection arm, Investigators will receive the PrismRA test results  and use the 
results to inform their treatment decision. PrismRA was developed and its performance 
characteristics determined by Scipher Medicine. The laboratory is certified under CLIA and 
accredited under CAP. Th is commercially available test is used for clinical purposes. It should 
not be regarded as investigational, or for research. The Investigator is expected to follow all 
aspects of the prescribing information when administering a pharmaceutical therapy in the c ourse 
of the treatment of patients included in this study. 
 
External control arm: 
Data arise from routine clinical practice and are not subject to study-specific safety assessm ent. 
 
9.2 Anticipated and Unanticipated Adverse Device Effects  
PrismRA arm: 
PrismRA is not expected to result in either anticipated or unanticipated adverse device effects 
(UADE) as it involves the analysis of ex-vivo blood samples from the participating patients.  
 
This study does include a potential source of harm to the patient as a result of the venipuncture 
procedure, unrelated to the study device: 
   Page 26 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  • Faintness, inflammation of the vein, bruising, temporary discomfort, and bleeding at the 
site of puncture may occur.  
• Infection may also occur, though rare. 
 
External control arm: 
Data arise from routine clinical practice and do not involve the use of the PrismRA test. Thus, no 
study-relevant adverse device effect exists. 
 
10 Statistical Considerations  
Data collected throughout this study will be analyzed by Sponsor or its designee.  
10.1 Sample size  
The study is powered to detect a difference of 10% in the proportion of patients with 
improvement in CDAI from baseline to Week 24 by at least MID as defined in Section 7.1 
between the PrismRA arm and the external control arm. Results are shown in Table 3. It is 
estimated that the attrition rate at Week 24 (defined as the proportion of patients with missing 
CDAI scores at Week 24 for any reason) can be up to 45% in the PrismRA arm and up to 50% in 
the external control arm. The sample sizes below have been inflated accordingly to account for 
the patient attrition mentioned above.   
 
With a sample size of 600 in the trial arm and 1,500 in the external control arm, the study has  
88% power to establish the superiority of the PrismRA intervention as compared to the standard 
of care by detecting a difference of 10% between the two study arms based on Fisher’s exact test 
of independent proportions assuming the proportion of patients with improvement in CDAI by 
MID are 40% and 30% in the PrismRA arm and the external control arm, respectively. 
 
Table 3. Study power for comparing proportion of patients with improvement in CDAI 
from baseline by at least MID between the two study arms 
Sample 
size in the 
trial arm 
before 
attrition Sample in 
the 
external 
control 
arm 
before 
attrition Proportion of 
patients in the 
PrismRA arm 
with MID 
improvement in 
CDAI  Proportion of 
patients in the 
external control 
arm with MID 
improvement in 
CDAI  Study 
power Alpha 
(two-
sided)  
600 1,000 0.45 0.35 80% 0.05 
600 1,000 0.40 0.30 82% 0.05 
600 1,000 0.35 0.25 85% 0.05 
600 1,500 0.45 0.35 86% 0.05 
600 1,500 0.40 0.30 88% 0.05 
600 1,500 0.35 0.25 90% 0.05 
600 2,000 0.45 0.35 88% 0.05 
   Page 27 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  600 2,000 0.40 0.30 90% 0.05 
600 2,000 0.35 0.25 92% 0.05 
 
The sample size calculation was performed with SAS (version 9.4, Cary, NC). 
 
10.2 Planned Interim Analysis  of the PrismRA Arm  
Data will be assessed by the Scipher Medicine team in one interim analysis when 50% of 
enrollees in the PrismRA arm have completed the treatment initiation visit. Refer to the s tudy’s 
SAP for additional details. 
 
10.3 Baseline Analysis  of the External Control Arm  
The OM1 team will identify an eligible pool of patients for an external control arm in the OM1’s  
PremiOM RA dataset. 
 
The baseline study data from the PrismRA arm will be provided by the Scipher Medicine team in 
a format ready for analysis (fully quality controlled), with a corresponding dataset specification 
document to help the OM1 team understand the data. 
 
From the pool of the study-eligible RA patients in the OM1 PremiOM RA dataset, the externa l 
control patients will be selected based on propensity scores. Analytic approaches which adj ust 
for differences in patient baseline characteristics will be used. These approaches include but  are 
not limited to propensity score weighting, matching and covariate adjustment in a multivariable 
regression model. 
 
Baseline covariates including the following will be considered (defined in a 6-month window 
prior to the index date unless otherwise specified elsewhere). 
 
Domain Variables 
Patient Characteristics • Age (calculated from birth year)  
• Sex 
• Race/Ethnicity  
• Geography  
• Body mass index  
Lifestyle • Smoking (current, former, or never 
smoker)  
Comorbidities (based on at least two 
diagnostic codes at least 30 days apart in the 
external control arm; based on an additional 
questionnaire in the PrismRA arm.) • Lung diseas e 
• Myocardial infarction  
• Other cardiovascular  
• Stroke  
• Hypertension  
• Fractures spine, hip, or leg  
• Depression  
• Diabetes mellitus  
   Page 28 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  • Ulcer or stomach problem  
• Fibromyalgia  
The Rheumatic Disease Comorbidity Index 
(RDCI) will be derived. 
RA Related • Duration of RA (Defined as the number 
of days between the date of the first RA 
diagnosis code and the index date for the 
external control arm)  
• Seropositivity (rheumatoid factor or anti -
citrullinated peptide antibody)  
• CDAI at baseline  
• Previous use of TNFi (yes, no)  
Concurrent RA Medications • Methotrexate  
• Folic acid  
• Non-methotrexate major csDMARDs 
(Sulfasalazine, Leflunomide, 
Hydroxychloroquine)  
• Glucocorticoids (with prednisone 
equivalent dose)  
 
 
 
 
 
The choice of TNFi vs. non-TNFi b/tsDMARDs as the study treatment will be excluded from the 
list of potential propensity score variables, as this variable is temporally subsequent to the  
study’s exposure variable (use or non-use of PrismRA in the trial arm and external control arm, 
respectively) and is considered a mediator of the potential benefit of PrismRA. 
 
The baseline characteristics of patients will be compared across the PrismRA arm  and the 
external control arm both before and after the propensity score modelling procedure in a table. In 
general, each continuous variable will be reported as mean, standard deviation (SD) or median, 
interquartile range (IQR), and range where appropriate. Each categorical variable will be 
summarized as a number and proportion. The baseline characteristics after propensity score 
modeling will be examined for improved covariate balance via the absolute standardized mean 
metric for each covariate. 
 
Complete details regarding the planned analyses are available in the study SAP.  
 
10.4 Planned Outcome Analysis  
The previously stated outcome measures will be compared across the PrismRA arm and the 
external control arm after propensity score modelling. For all outcome measures, point estimate s 
as well as two-sided 95% confidence intervals (CIs) will be provided. Hypothesis testing will be 
   Page 29 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  two-sided with an alpha level of 5%. For proportion outcome measures, Pearson’s χ2 test will be 
utilized. For continuous outcome measures, unpaired t- test will be used. 
 
Refer to the study’s SAP for additional details. 
 
10.5 Missing Data Handling  
Missing data will be handled with two approaches: (1) minimizing the chance of missing data in 
the study design and conduct stages, and (2) handling missing data with statistical methods in the 
analysis phase. 
 
The following measures will be taken to reduce missing data in the analysis datasets. 
 
PrismRA arm: 
Missing data will be minimized through rigorous conduct of data collection as described in 
Section 8.9. See below for the handling of missing follow-up data. 
 
External control arm: 
At least one observed CDAI in the 3-month period prior to the index date (b/tsDMARD 
initiation) will be required to ensure patients are selected from practices where CDAI a re 
recorded as a part of routine care.  
 
The following statistical methods will be considered in handling missing data in the analys es. 
 
• For outcome measures, the appropriate methods depend on the magnitude of missing 
data, and whether data are assumed to be missing at random. This will be evaluated prior 
to the final analysis and will be evaluated for the PrismRA arm and the external control 
arm separately. Considerations will be given to multiple imputation, estimating the CDAI 
outcome (whether MID was achieved at Week 24) based on previous outcome measures 
and treatment status, and complete case analyses. A sensitivity analysis will be c onducted 
to assess the robustness of the analysis results. Details will be provided in the SAP.  
10.6 Data Reporting  
10.6.1  Interim Analyses and Reporting 
A single interim analysis will be conducted at the time that 50% of PrismRA arm patients  (the 
first 300 patients enrolled) have completed Visit 2 or have dropped out of the study.  All data 
available in the PrismRA arm at the time of the interim analysis will be included, but  
effectiveness of PrismRA will not be evaluated to protect the integrity of the study. Instead, the 
interim analysis will be restricted to baseline characteristics and data comple teness analyses. 
 
10.6.2  Final Analyses and Reporting 
A final study report will be generated after all data collection is complete. The final report w ill 
encompass all planned analyses, including a description of the complete study population and 
study results, as described in the SAP. 
   Page 30 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005   
11 Limitations  
11.1 Data Recency  
An ideal observational external control arm is fully contemporaneous to the single arm trial wit h 
prospective real-world data collection specifically tailored to the corresponding PrismRA arm14.  
The approach is based on retrospective real-world data collection (secondary use of routinely 
collected data). Due to the need to have enough patients for the propensity score process, the 
external control arm may have a mixture of contemporaneous external control patients (observed 
during the PrismRA arm study period) and historical external control patients (observed before 
the PrismRA arm study period). In the SOC for RA, an increasing uptake of late-comer 
b/tsDMARDs has been reported for the 2001–2015 time period 15. The market uptake trend may 
have be en less dramatic in the more recent time period due to the paucity of new FDA approvals 
(last FDA approval: upadacitinib in 2019) and market saturation. However, the recent 
announcement (September 2021) by the FDA of a boxed warning for JAK inhibitors’ regarding 
cardiovascular safety may have had an influence. In the current study, the historical external 
control patients will be limited to those who initiated their index b/tsDMARDs with the 1-3 year 
period prior to the trial enrollment (March 2022; minimum years that allows sufficient 
propensity score model patients). This approach should minimize the potential impact of a 
secular trend in the SOC (particularly the increasing uptake of non-TNFi b/tsDMARDs) while 
allowing for sufficient power.  
 
11.2 RA Patient Identification  
External control arm: 
The identification of RA patients in the external control arm is based on the claims algorithm 
implemented in OM1’s PremiOM RA dataset rather than the 2010 ACR/EULAR classification 
criteria. The algorithm uses RA diagnostic codes as well as DMARDs use. The combination of 
RA diagnostic code and DMARD use has a high positive predictive value (86.2%-88.9% against 
physician diagnosis gold standard) 16 and is a well-accepted standard in the real-world data 
studies of RA. The OM1 claims algorithm likely has a higher positive predictive value as it 
incorporates further exclusion of patients with non-RA diagnoses for which DMARDs are 
indicated. 
 
12 Data Handling and Record Keeping  (Study Management)  
PrismRA arm: 
The design and conduct of the PrismRA arm will be governed by Scipher Medicine and its 
designees. OM1 will provide input to ensure the smooth execution of the subsequent analyses. 
 
External control arm: 
The design and execution of the observational external control arm and subsequent analyses wi ll 
be performed by OM1, with the guidance, input, review, and approval of the Scipher Medicine 
   Page 31 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  team . To ensure the quality and integrity of research, this study will be conducted under the 
Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society 
for Pharmacoepidemiology (ISPE), the principles outlined in the Belmont Report (Ethical 
Principles and Guidelines for the Protection of Human Subjects of Research), and any applicable 
national guidelines. 
 
12.1  Study  Database  
PrismRA arm: 
Data will be collected into the study database through a secure, electronic database ca pture 
(EDC) system or an electronic data transfer via an encrypted secure sockets layer protocol to the 
Scipher Medicine data lake.  
Electronic case report forms will be maintained in the EDC, and all relevant observations and 
data related to the protocol-defined assessments will be recorded. This will include, at m inimum, 
demographics, medical history, physical examinations, laboratory results, clinical ass essments, 
treatment information, and patient reported outcomes.  
Prior to recording data in the paper CRF, Investigators and site staff will be trained on how to 
accurately capture data. Trained and qualified Investigators and site staff will be responsible for 
recording data in the paper CRFs. 
The study database will be password protected and access will be provided only to trained and 
authorized personnel. Data collected into the study database may include protected health 
information (PHI). This PHI will not be shared beyond the Sponsor/designee or site without 
specific institutional review board (IRB) approval and additional patient consent.  
 
External control arm: 
An analytic dataset of eligible RA patients, built upon the underlying OM1 enterprise data 
warehouse, will be created for this study. The OM1 data warehouse is built on OM1 Origin 
Plus™, a scalable cloud computing platform with high availability and dependability. The 
analytic dataset will contain data ingested from multiple sources in multiple formats  and will 
serve as a repository of centralized, standardized, normalized, and integrated data from the 
different sources. Where necessary and possible, data from disparate sources will be linked with 
other data that are attributed to a common patient creating a longitudinal record. Data will be 
standardized and normalized as necessary, for example, classifications of text documents such as  
lab reports and pathology reports. A detailed technical data management plan describing 
processes for transferring data, managing data quality, and maintaining data security will be 
developed and implemented for the study. 
 
12.2 Inspection of Records  
PrismRA arm:  
Sponsor or its designee will be allowed to conduct site visits either remotely or at the 
Investigator’s clinical research facilities for the purpose of monitoring any aspect of the study, as 
   Page 32 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  applicable. The Investigator agrees to allow the Sponsor or its designee to inspect the faci lities, 
patient medical records, source documents, and other records relative to study conduct. Source 
documents containing PHI will be protected and transferred to the Sponsor or its designee via a 
secure, HIPAA compliant portal. Study records containing patient health information will be 
maintained in a confidential manner. 
 
12.3 Retention of Records  
PrismRA arm:  
All primary data collected as a result of the original observations and activities of the st udy and 
that are necessary for the reconstruction and evaluation of any study report will be retained in a 
secure archive at the study site for a period not less than 6 years after the last approval of a 
marketing application in an International Council for Harmonization (ICH) region, and until 
there are no pending or contemplated marketing applications in an ICH region, or until at least 6 
years have lapsed since the formal discontinuation of the clinical development of the 
investigational product. All country and region-specific requirements that may be more stringent 
than the 6 years included in ICH shall be followed. 
The site will maintain an Investigator Site File (ISF), which will be maintained at t he study site 
and in accordance with local and Federal regulations, as applicable. The site must keep this IS F 
current and available for review by the Sponsor, IRB, and/or regulatory bodies. 
 
External control arm: 
Based on recommendations from International Society for Pharmacoepidemiology Guidelines 
for GPP, all analysis datasets used for the final analysis will be archived for at least five ye ars 
after the delivery of the final tables to Scipher Medicine unless specific requests are made  during 
the report process. 
 
12.4 Confidentiality  (PrismRA arm  Only)  
12.4.1  Confidentiality of Records  
PrismRA arm:  
All study sites, laboratories, and parties supporting this study must comply with HIPAA, where 
applicable. All data and records generated throughout this study will be kept confidential in 
accordance with local and Federal policies and HIPAA on patient privacy.   
At consent, personal identifying information, including patient name, birth date, and contact 
information, will be collected and stored on a secure and HIPAA-compliant research database .  
Following consent, each patient will be assigned a unique study identification number that wil l 
be used to track their de-identified data.  
Records that may have patient identifying information will be kept confidential in accordance 
with applicable guidelines, regulations, and laws.  
   Page 33 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005   
 
External control arm: 
The study utilizes a de-identification and secure patient key software tool to create stat istically 
de-identified data sets and to create de-identified keys for patients. The tool generates tokens 
based on a patient’s primary information (first name, last name, date of birth, and gender) and all 
study analysis performed will use the statistically de-identified data. Only a few limite d data set 
data elements, including dates of service and date of death, will be part of the study data set. All 
parties will ensure protection of patient personal data and will not include patient identifiabl e 
information on any study forms, reports, publications, or in any other disclosures, except where 
required by law. 
 
The database is housed on a secure cloud computing platform on which all OM1 technical 
operations, data processing, and storage are conducted. The global infrastructure is designed and 
managed according to security best practices as well as a variety of security compliance 
standards making it one of the most secure computing infrastructures in the world. The system 
also meets the standards of the ICH E6 (R2) guideline regarding electronic study data handling 
and is available for audit upon request. Patient confidentiality will be strictly maintained.  
 
12.4.2  Review of Records 
Sponsor and/or its designee will review source documents (i.e., medical records, laboratory 
results) and data collected throughout the study. In addition, an auditor, IRB, FDA , or national or 
local regulatory authorities may access and review applicable source documents, records, and 
data. All patients will be notified of and consent to this possibility during the consenting proces s. 
 
12.4.3  Study results 
 If any results of the study are published, the patient’ s identity will remain confidential. 
 
12.4.4  Future Use of Data or Specimens 
PrismRA arm: 
Data collected throughout the study and subsequently de-identified will be used for future 
research and/or distributed to other investigators for future research.  
PrismRA samples from patients processed at Scipher Medicine’s CLIA-certified CAP-accredit ed 
laboratory will also be de-identified and used for future research and/or distributed to other 
investigators for future research. Future research will include extracting and sequencing DNA 
isolated from the blood samples, in addition to the RNA that is extracted and sequenced for 
PrismRA. Future research may also include discovering novel biomarkers for disease diagnosis, 
monitoring, or progression as well as discovering new disease mechanisms, therapeutic targets, 
and therapies for autoimmune disorders.   
   Page 34 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  De-identified data may be stored indefinitely, and de-identified specimens may be stored for up 
to 10 years following study completion. The de-identified data and specimens may be shared 
with researchers/institutions outside of Scipher without additional informed consent from the 
subject or the legally authorized representative. This could include for-profit companies. 
 
External control arm: 
Patients in the external control arm are from the OM1 PremiOM RA dataset, owned and 
maintained by OM1. OM1 PremiOM RA data may be used for analyses in the future per 
agreement.  
 
13 Ethics  
13.1  Ethics Review  
The protocol, ICF, and any advertisements must be approved or given a favorable opinion in 
writing by an IRB. The Investigator must submit written and dated verification of the IRB 
approval to Sponsor before he or she can enroll any patient into the study. 
The Sponsor/designee or Investigator will inform the IRB of any amendment to the protocol in 
accordance with local requirements. The protocol must be re-approved by the IRB upon receipt 
of amendments and annually, if required per local and IRB regulations. 
Initial IRB approval, and all materials approved by the IRB for this study including the patient 
consent form and recruitment materials must be maintained by the Investigator and made 
available for inspection. 
 
13.2 Ethical Conduct of the Study  
The Sponsor, Investigators, study staff and designees will conduct the study in accordance with 
the ethical principles that have their origin in the Declaration of Helsinki and are consistent  with 
ICH, GCP, and other applicable local and federal laws, regulations, and guidelines. 
14 Quality Control  
14.1 Data Quality  
PrismRA arm: 
Site and data monitoring will occur in accordance with the clinical monitoring plan, if applicable . 
Data captured in the study database will be compared against the source data for completeness  
and accuracy. Discrepancies will be addressed and corrected, if required, by qualified site 
personnel.  
   Page 35 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  eCRF data will also be routinely reviewed for timeliness, errors, accuracy, and omissions. Any 
data issues will be submitted to the site for further clarification. Qualified site personne l will 
address queries and correct data in the study database or paper source files. 
14.2 Protocol Deviations  
PrismRA arm: 
Study sites and databases will be evaluated for protocol deviations.  
At study completion, the number and type of protocol deviations will be analyzed by the study 
biostatistician to review the events by site to determine if the deviations could affect the  integrity 
of the study data. The study biostatistician will report findings to the Sponsor.  
15 Protocol revision history  
Rev. #  Effective Date  Summary of Changes  
3.0 20-Oct-2022 Change to an external control arm design and sample 
size adjustment. 
2.0 04-Feb-2022  Change in study title, endpoints, clarification of study 
design, and general edits.  
1.0 23-Jul-2021  Initial Release  
 
  
   Page 36 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  16 References  
1. Spencer AK, Bandaria J, Leavy MB, Gliklich B, Su Z, Curhan G, Boussios C. Validat ion of a 
machine learning approach to estimate Clinical Disease Activity Index Scores for rheumatoid arthritis. 
RMD Open. 2021 Nov;7(3):e001781. doi: 10.1136/rmdopen -2021 -001781. PMID: 34819386; PMCID: 
PMC8614150.  
2. Felson  DT, Anderson  JJ, Boers  M, et al. America n College  of Rheumatology.  Preliminary  
definition  of improvement  in rheumatoid  arthritis.  Arthritis  Rheum  1995;  38(6): 727-35. 
3. Charles -Schoeman  C, Burmester  G, Nash  P, et al. Efficacy  and safety  of tofacitinib  following  
inadequate  response  to conventional  synthetic  or biological  disease -modifying  antirheumatic  drugs.  Ann 
Rheum  Dis 2016;  75(7):  1293 -301. 
4. Bykerk  VP, Ostor  AJ, Alvaro -Gracia  J, et al. Tocilizumab  in patients  with active  rheumatoid  
arthritis  and inadequate  responses  to DMARDs  and/or  TNF  inhibitors:  a large,  open -label  study  close  to 
clinical  practice.  Ann Rheum  Dis 2012;  71(12):  1950 -4. 
5. Fleischmann  R, van Adelsberg  J, Lin Y, et al. Sarilumab  and Nonbiologic  Disease -Modifying  
Antirheumatic  Drugs  in Patients  With  Active  Rheumatoid  Arthritis  and Inadequate  Response  or 
Intolerance  to Tumor  Necrosis  Factor  Inhibitors.  Arthritis  Rheumatol  2017;  69(2): 277-90. 
6. Genovese  MC, Schiff  M, Luggen  M, et al. Efficacy  and safety  of the selective  co-stimulation  
modulator  abatacept  following  2 years  of treatment  in patients  with rheumatoid  arthritis  and an inadequate  
response  to anti-tumour  necrosis  factor  therapy.  Ann Rheum  Dis 2008;  67(4): 547-54. 
7. Jin Y, Desai  RJ, Liu J, Choi  NK, Kim SC. Factors  associated  with initial  or subsequent  choice  of 
biologic  disease -modifying  antirheumatic  drugs  for treatment  of rheumatoid  arthritis.  Arthritis  Res Ther  
2017;  19(1): 159. 
8. Curtis  JR, Zhang  J, Xie F, et al. Use of oral and subcutaneous  methotrexate  in rheumatoid  
arthritis  patients  in the United  States.  Arthritis  Care  Res (Hoboken)  2014;  66(11):  1604 -11. 
9. Mellors  TW, Johanna;  Ameli,  Asher;  Jones,  Alex;  et al. Clinical  valida tion of a blood -based  
predictive  test for stratification  of response  to anti-TNF  therapies  in rheumatoid  arthritis  patients.  
Network  and Systems  Medicine  Volume  3.1, 2020  doi: 10.1089/nsm.2020.0007.  Accepted  June 2020 . 
10. Cohen  s, Wells  AF, Curtis  JR, Dhar  R, Mellors  T, Zhang  L, Withers  JB, Jones  A, Ghiassian  SD, 
Wang  M, Connolloy -Strong  E, Rapisardo  S, Gatalica  Z, Pappas  DA, Kremer  JM, Saleh  A, Akmaev  VR. 
A Molecular  Signature  Response  Classifer  to Predict  Inadequate  Response  to Tumor  Necrosis  Factor -α 
Inhibitors:  The NETWORK -004 Prospective  Observational  Study.  Rheumatol  Ther.  2021  Jun 19:1-18. 
doi:10.1007/s40744 -021-00330 -y. 
11. Curtis JR, Yang S, Chen L, Pope JE, Keystone EC, Haraoui B, Boi re G, Thorne JC, Tin D, 
Hitchon CA, Bingham CO 3rd, Bykerk VP. Determining the Minim ally Important Difference in the 
Clinical Disease Activity Index for Improvement and Wo rsening in Early Rheumatoid Arthritis Patients. 
Arthritis Care Res (Hoboken). 2015 Oct;67(10):1345 -53. doi: 10.1002/acr.22606. PMID: 25988705; 
PMCID: PMC4580563.  
12. Ward MM, Castrejon I, Bergman MJ, Alba MI, Guthrie L C, Pincus T. Minimal Clinically 
Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. J 
Rheumatol. 2019 Jan;46(1):27 -30. doi: 10.3899/jrheum.180153. Epub 2018 Oct 15. PMID: 30323010; 
PMCID: PMC6314888.  
13. Wolfe F, Michaud K. Assessment of pain in rheumatoid  arthritis: minimal clinically significant 
difference, predictors, and the effect of anti -tumor necrosis factor therapy. J Rheumatol. 2007 
Aug;34(8):1674 -83. Epub 2007 Jul 1. PMID: 17611989.  
14. Burcu M, Dreyer NA, Franklin JM, Blum MD, Critchlow CW, Perf etto EM, Zhou W. Real -world 
evidence to support regulatory decision -making for medicines: Considerations for external con trol arms. 
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1228 -1235. doi: 10.1002/pds.4975. Epub 2020 Mar 11. 
PMID: 32162381; PMCID: PMC7687199.  
   Page 37 of 37 
 
Scipher Medicine Corporation  Confidential  SCIPHER -RA-005  15. Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal Trends in Use of Biologic 
DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and 
Privately Insured Patients. J Manag Care Spec Pharm. 2017 Aug;23(8):809-814. doi: 
10.18553/jmcp.2017.23.8.809. PMID: 28737992.  
16. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz  JN, Solomon DH. Valid ation of 
rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011 Feb 23;13(1):R 32. 
doi: 10.1186/ar3260. PMID: 21345216; PMCID: PMC3241376.  
 
 